Eli Lilly and Company (NYSE:LLY) Shares Down 1.2% – Time to Sell?

Eli Lilly and Company (NYSE:LLY) traded down 1.2% during mid-day trading on Thursday . The stock traded as low as $967.10 and last traded at $974.8210. 3,346,273 shares changed hands during trading, an increase of 4% from the average session volume of 3,208,447 shares. The stock had previously closed at $987.05.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 beat-and-raise: Lilly reported a blowout Q1 with outsized revenue and raised guidance, which drove the recent rally and underpins long-term growth expectations. LLY Stock Pops 16% After Beat-and-Raise Q1
• Positive Sentiment: Product momentum: Oral GLP‑1 Foundayo and injectable Mounjaro remain major revenue drivers (Mounjaro is now the world’s top-selling drug), supporting earnings visibility and premium valuation. Lilly’s Oral GLP-1 Pill Foundayo Starts Strong
• Positive Sentiment: Capacity build: Lilly pledged another $4.5B to expand Indiana manufacturing (bringing total commitments >$21B), reducing future supply risk and supporting rollout scale-up for GLP‑1s and biologics. Lilly commits additional $4.5 billion across Indiana manufacturing sites
• Neutral Sentiment: Analyst stance and risk framing: Firms like Guggenheim reiterated buy ratings and some boutiques argue the market overreacted to an FDA adverse-event report—supporting the view that current pullbacks may be tactical rather than fundamental. Wolfe Research says market reaction appears overdone Guggenheim reiterates Buy
• Negative Sentiment: Financing chatter: Reports that Lilly plans to sell roughly $8B of bonds to fund acquisitions have spooked some traders—new debt (or M&A) can raise short-term uncertainty around capital allocation. Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds
• Negative Sentiment: Competitive pressure: Novo’s strong oral GLP‑1 launch and raised guidance highlight that the obesity/weight‑loss market is evolving quickly; increased competition could weigh on Lilly’s market share and pricing over time. Novo Nordisk Could Win the Oral GLP-1 Race

Analyst Ratings Changes

Several equities research analysts recently issued reports on LLY shares. Argus upped their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a research report on Monday, February 9th. CICC Research increased their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a report on Wednesday, February 11th. Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, May 1st. Scotiabank restated an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Barclays upped their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,217.59.

Eli Lilly and Company Stock Performance

The company’s 50 day simple moving average is $945.26 and its 200 day simple moving average is $989.70. The stock has a market cap of $918.03 billion, a price-to-earnings ratio of 34.63, a PEG ratio of 1.08 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period last year, the firm posted $3.34 earnings per share. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 35.58 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

Several large investors have recently made changes to their positions in the business. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company in the fourth quarter worth approximately $25,000. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $30,000. Miller Global Investments LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $33,000. Finally, E Fund Management Hong Kong Co. Ltd. boosted its position in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the period. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.